Slide 1: Immuron CEO to present at Sharewise
Immuron CEO, Steven Lydeamore to present at Sharewise Melbourne, Australia, July 9, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at Sharewise
Slide 2: For personal use only
tract delivering its full benefits directly to the bacteria found there. The underlying nature of Immuron’s platform technology enables the development of medicines across a large range of infectious diseases. The platform can be used to block viruses or bacteria at mucosal surfaces such as the Gast
Slide 3: Forward-looking statements and references
Sears KT, Tennant SM, Reymann MK, Simon R, Konstantopolos N, Blackwelder WC, Barry EM and Pasetti MF. Bioactive Immune Components of Anti-Diarrheagenic Enterotoxigenic Escherichia coli Hyperimmune Bovine Colostrum products. Clinical and Vaccine Immunology. 24 (8) 1-14; 2017. Steffen R. Epidemiology
Slide 4: Sharewise Webinar
NASDAQ: IMRN ASX: IMC For personal use only Sharewise Webinar Steven Lydeamore Chief Executive Officer 9 JULY 2024
Slide 5: Safe Harbor Statement
SAFE HARBOR STATEMENT C e r t a i n s t a t e m e nt s m a d e i n t h i s p re s e nt a t i o n a re fo r wa rd - l o o k i n g s t a t e m e nt s a n d a re b a s e d o n I m m u ro n ’s c u r re nt ex p e c t a t i o n s , e s t i m a t e s a n d p ro j e c t i o n s . Wo rd s s u c h a s “a nt i
Slide 6: Executive summary
Executive summary Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases For personal use only Company Overview Financial Snapshot Two commercially available
Slide 7: Technology platform
Technology platform Immuron’s proprietary technology platform For personal use only combines the natural human nutrition & health benefits of bovine colostrum with a novel class of specifically targeted oral polyclonal antibodies that offer delivery within the gastrointestinal (“GI”) tract and can b
Slide 8: Travelan Mechanism of action
Travelan® | Mechanism of action Pre-Clinical Studies For personal use only Broad spectrum antimicrobial Protects against bacterial Binds to surface layer proteins Toxin neutralization and adhesion to host cell intestinal preventing bacterial clearance of targeted gut epithelia colonization and motil
Slide 9: Status of product portfolio and key milestones
Status of product portfolio and key milestones Travelan® Clostridioides difficile Immuron’s Clinical Programs For personal use only MTEC 21-10-013 grant Phase 2 IMM-529 randomized clinical challenge study to Prevention of recurrent CDI infections Compound or examine a dosing regimen for Travelan® Va
Slide 10: Addressable market & industry overview
Addressable market & industry overview Billion Dollar Market For personal use only Traveller’s diarrhoea treatment market is large and growing at a CAGR of ~7% Industry tailwinds Travel picking up significantly following COVID lockdowns Frequent Symptom 30% - 70% of travelers experience traveller’s
Slide 11: Travelan sales continue strong growth
Travelan® sales continue strong growth Global For personal use only + FYTD Mar 2024 AUD$3.6 million up 154% on (prior comparative period) pcp + Mar 2024 Quarter AUD$1.3 million up 51% on pcp and 75% on last quarter Australia + FYTD Mar 2024 AUD$2.8 million up 234% on pcp + Mar 2024 Quarter AUD$0.9 m
Slide 12: Positive results support Travelan progress to phase
Positive results support Travelan® progress to phase 3 IMM-124E Phase 2 For personal use only Travelan® topline clinical + Healthy volunteers were recruited and randomized to receive a single daily oral dose of 1200 mg of Travelan® or placebo. Dosing commenced 2 days trial results demonstrate prior
Slide 13: World first triple mechanism of action for CDI
WORLD FIRST TRIPLE MECHANISM OF ACTION FOR CDI IMM-529: pre-IND filed with FDA July 2024 Indication / Target IMM-529 will be indicated for the treatment of recurrent C. difficile For personal use only Population infection Product • Novel antibody-containing therapeutic which neutralizes C. difficile
Slide 14: Scientific references
Scientific references Travelan® (IMM-124E) Travelan® has been shown to reduce both the incidence and severity of ETEC- For personal use only Scandinavian Journal of Gastroenterology, 46:7-8, 862-868, DOI: 10.3109/00365521.2011.574726 induced diarrhea in up to 90% of volunteers Clinical Evaluation of
Slide 15: Steven Lydeamore contact information
For personal use only STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172